Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $49
SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS -0.06% Pre
SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS SLN | 18.07 18.07 | -0.06% 0.00% Pre |
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:
SLN) with a Overweight and raises the price target from $45 to $49.